HLHong Liu

Hong Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hong Liu has a total of 110 co-authors. Here are the top co-authors by number of shared publications:

  • Lu Zhou

    Hematology department Affiliated Hospital of Nantong University Nantong China

    5 shared publications
  • Hui Jia

    Department of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, People’s Republic of China

    3 shared publications
  • Huiping Shi

    Soochow University Medical College

    3 shared publications
  • Yaping Zhang

    Hematology Department, Affiliated Hospital of Nantong University, Nantong, People's Republic of China

    3 shared publications
  • Z H Lin

    Medical School, Nantong University, Nantong 226001, China Affiliated Hospital of Nantong University, Nantong 226001, China

    3 shared publications
  • Zenghua Lin

    Department of Hematology Affiliated Hospital of Nantong University Nantong China

    3 shared publications

Latest Publications

  • Open Access

    Resveratrol-activated PI3K/AKT/mTOR signaling pathway attenuates ferroptosis by promoting NRF2/GPX4 metabolic pathway to mitigate IFN-gamma-mediated aplastic anemia

    by Erhao Zhang, Jianan Cui, Xinran Zhu, Juan Chen, Liqin Xu, Xiaomin Li, Yufei Zhang, Hui Jia, Xiaorong Zhou, Zenghua Lin, et al.

    Background: Aplastic anemia (AA) is a severe hematological disorder caused by hyperactivated T cell-mediated hematopoietic failure. It is characterized by hematopoietic stem cell deficiency and hypocellular hematopoiesis in the bone marrow (BM). Ferroptosis, a specific type of programmed cell death, is defined by iron-dependent lipid peroxidation, which has garnered the attention of researchers due to its unique role and biological importance in various diseases. However, the correlation between immunological imbalance-induced ferroptosis and the mortality of hematopoietic stem cells within the BM microenvironment in AA is unclear. Resveratrol (RSV) is crucial in activating NRF2, hence influencing the onset and progression of diseases by regulating ferroptosis. This study aimed to investigate the roles and molecular mechanisms of RSV in the hematopoietic recovery of AA regarding ferroptosis. Methods: We measured some biomarkers in AA mice and IFN-gamma-treated 32D cells, representing AA syndromes and ferroptosis features. Furthermore, in RSV-treated 32D AA cells, cell activity, cell apoptosis, mitochondrial membrane potential, mitochondrial membrane permeability, and intracellular levels of MDA, ferrous iron, 4-HNE, GSH, ROS, and lipid peroxidation were assessed. Subsequently, additional in vitro and in vivo experiments were performed to investigate the mechanisms by which RSV effectively regulates NRF2 stability, further inhibiting ferroptosis in AA. Results: We demonstrated that ferroptosis contributes to the occurrence and development of AA disease. RSV dose-dependently inhibits ferroptosis in 32D AA cells by targeting GPX4 expression, enhancing the cell activity of hematopoietic BM cells. Mechanically, RSV significantly increases NRF2 phosphorylation through the PI3K/AKT/mTOR signaling pathway, which maintains NRF2 stability to promote the GPX4 metabolic pathway in AA. Protein levels of p-AKT, p-mTOR, p-NRF2, and GPX4 were markedly increased in BM cells in RSV-treated AA mice, resulting in the suppression of AA development. Conclusion: Our data demonstrate that RSV effectively inhibits ferroptosis in AA or IFN-gamma-treated 32D cells by targeting the PI3K/AKT/mTOR signaling pathway, which enhances NRF2-mediated GPX4 transcription, thereby ameliorating AA symptoms in vitro and in vivo. This study concludes that RSV is a potential therapeutic drug for ferroptosis-related AA treatment.

  • Open Access

    Publisher Correction: Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma

    by Guihua Zhang, Shengya Cao, Chong Geng, Yueyue Sun, Jinge Xu, Chong Chen, Faan Miao, Huanxin Zhang, Yunxin Kong, Rongke Jiang, et al.

  • Open Access

    Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma

    by Guihua Zhang, Shengya Cao, Chong Geng, Yueyue Sun, Jinge Xu, Chong Chen, Faan Miao, Huanxin Zhang, Yunxin Kong, Rongke Jiang, et al.

    Multiple myeloma (MM) remains incurable, as most patients relapse or become refractory (RRMM), and the molecular nexus among clonal evolution, immune escape and therapy response remains unknown. Bulk RNA-seq from 24 MM to 6 matched marrows (subset of 132) plus single-cell datasets were analysed by differential expression, pseudotime, WGCNA, enrichment, immune deconvolution and GDSC drug screens. PRKD2 was knocked down (KD) or over-expressed (OE) in H929, 8226 and U266 cells. Viability (CCK-8) and apoptosis (Annexin V/7-AAD) were assessed after 48 h of axitinib (1.25–10 µM). PRKD2 was the sole gene uniformly up-regulated in newly diagnosed MM, RRMM and poor-survival cohorts, rising along the malignant plasma-cell trajectory. High PRKD2 aligned with ISS-III stage, elevated mRNAsi/EREG_mRNAsi and worse 5-year survival (38% vs. 73%, P = 0.012). PRKD2-KD reduced proliferation (~ 30%) and restored HLA-E, whereas PRKD2-OE suppressed antigen-presentation genes and polarised macrophages toward an IL-6/MERTK tumour-promoting phenotype. PRKD2-high marrow contained more naïve/memory B cells but fewer mature plasma cells. PRKD2 expression correlated positively with axitinib sensitivity (– log10 IC50, r = 0.68; P < 0.001). Experimentally, PRKD2-OE cells showed a 1.4-fold increase in axitinib-induced apoptosis, while PRKD2-KD cells were intrinsically pro-apoptotic and further sensitised; axitinib abolished the growth advantage conferred by PRKD2-OE. PRKD2 integrates secretory stress, stem-like programmes and immune evasion, driving aggressive MM yet exposing a vulnerability to VEGFR/PDGFR blockade. Direct PRKD2 targeting or axitinib-based combinations—including proteasome inhibition—deserve clinical evaluation for high-risk MM.


  • Open Access

    Bone marrow metastasis of gastric signet ring cell carcinoma complicated by thrombotic microangiopathy: A case report

    by Wei Sun, Xiao-Ci Chen, Han Wang, Wei-Yu Chang, Yun He, Zeng-Hua Lin, Hui Jia, Xiao-Mei Zhang, Hong Liu

    BACKGROUND Thrombotic microangiopathy (TMA) is an acute syndrome characterized by microangiopathic hemolytic anemia, thrombocytopenia, and multi-organ dysfunction due to the microcirculation of platelet thrombi. Cancer-associated TMA is a rare and fatal complication, which often occurs during cancer remission. It is frequently misdiagnosed because of limited clinical awareness. CASE SUMMARY A middle-aged female patient presented to our clinic with a 15-days history of back pain, 15 months post-gastrectomy. Cancer-associated TMA was confirmed through bone marrow aspiration, biopsy, and imaging. The patient received intermittent transfusions, fluids, nutrition, and microcirculation therapy with partial coagulation improvement. The family refused intensive care unit admission and plasma exchange, preferring palliative care. The patient died of cerebral hemorrhage and herniation due to disease progression. This case indicates that TMA may serve as an early manifestation of various malignancies, particularly gastric cancer. However, it is often misdiagnosed. Its pathogenesis is not well understood and needs to be further investigated. Currently, no standardized treatment have been developed. Plasma exchange is the only intervention available, though other therapies may also be effective. CONCLUSION In this case of gastric signet-ring cell carcinoma complicated by TMA, the patient achieved transient remission with supportive care but died following treatment discontinuation. Further studies are needed to elucidate the pathological mechanisms and therapeutic strategies for cancer-associated TMA.

  • Open Access

    Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma

    by Yuejiao Huang, Yiming Gong, Xiang Liu, Huaying Ruan, Jinhua Lu, Hosein Kouros-Mehr, Hong Liu, Han Wang

    CD19-directed CAR T-cell therapy is a breakthrough immunotherapy for B-cell malignancies. However, CD19 loss-mediated relapsed/refractory disease continues to pose a significant challenge, highlighting the urgent need for CAR T cells targeting alternative antigens. To address this issue, we developed a CD20-directed CAR T incorporated with an additional CD30-directed binder to enhance cytotoxicity toward cancer cells. Here, we report that a patient with bulky transformed follicular lymphoma was successfully treated with CD20/CD30-directed CAR-T cells. The patient received two doses of anti-CD20/CD30-CAR-T therapy administered one month apart. Complete metabolic remission was achieved 1 month after the first infusion without evidence of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). The second dose was given as a consolidation therapy with sustained disease-free survival exceeding 12 months to date. The report underscores the promising therapeutic potential and safety profile of CD20/CD30-directed CAR T-cell therapy.Clinical Trial Registration: https://www.clinicaltrials.gov, identifier NCT06756321.


  • Open Access

    Rediscovering hemostasis abnormalities in multiple myeloma: The new era

    by Yudie Huang, Chongyu Wang, Hua Wang, Hong Liu, Lu Zhou


  • Open Access

    [Homing and characteristic analysis of macrophage in immune-mediated aplastic anemia model mice].

    by W Sun, Z H Lin, H Wang, H Jia, L G Tong, Z P Zhang, W Li, C C Zhou, H Liu

    To investigate the dynamic homing process and characteristics of macrophages in different organs of immune-mediated aplastic anemia (AA) model mice. Macrophages in donor lymph nodes were sorted by magnetic beads and labeled with PKH67. After modeling according to the preparation method of the AA model, peripheral blood rountine analysis, bone marrow biopsy and HE staining results were analyzed to verify the modeling effect. On days 4, 8, and 12 of modeling, the bone marrow, spleen, and lymph node mononuclear cells were collected, and dynamic changes of PKH67-labeled macrophages in donor mice were analyzed by flow cytometry. In this study, dynamic changes in PKH67-labeled macrophages in the pathogenesis of AA model mice were explored. Macrophages in donor mice homed to the lymph nodes, expanding and differentiating in the lymph nodes, and finally transported to the bone marrow and spleen. Through proteomics mass spectrometry analysis, the related immune inflammatory response pathway of macrophages involved in the activation of the AA bone marrow microenvironment was preliminarily revealed, which provides a basis for the pathological macrophages involved in the pathogenesis of AA model mice.

  • Open Access

    [Efficacy and safety analysis of hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in low-risk myelodysplastic syndromes patients].

    by Y Lyu, Z H Lin, L Yang, H Liu

    Myelodysplastic syndromes is a heterogeneous group of myeloid neoplastic disorders originating from hematopoietic stem cells and manifesting as pathological bone marrow hematopoiesis and a high risk of transformation to acute myeloid leukemia. In low-risk patients, the therapeutic goal is to improve hematopoiesis and quality of life. Roxadustat is the world's first oral small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, which, unlike conventional erythropoietin, corrects anemia through various mechanisms. In this study, we retrospectively analyzed the changes in anemia, iron metabolism, lipids and inflammatory indexes in patients with low-risk myelodysplastic syndromes to evaluate its therapeutic efficacy and safety, and to provide theoretical and practical data for the application of roxadustat in myelodysplastic syndromes.


  • Increased expression of CEP72 predicts poor prognosis in multiple myeloma

    by Dan Guo, Jinfeng Lu, Hao Ji, Zenghua Lin, Lemin Hong, Hongming Huang, Hong Liu

    Introduction: Multiple myeloma (MM) is a fatal hematological malignancy and does not have adequate prognostic indicators. Previous studies indicate that CEP72 is closely related to tumorigenesis and tumor progression. However, the expression and function of CEP72 in multiple myeloma have yet to be elucidated.Methods: In this study, we explored the correlation between CEP72 expression and clinicopathological characteristics as well as the impacts of CEP72 expression on the survival of MM patients. In addition, PPI, GSEA and Chemotherapy drug resistance analysis identified the possible mechanism.Results: CEP72 is overexpressed in both MM patients and MM cell lines. Clinically, patients in the CEP72(high) subgroup were significantly older than those in the CEP72(low) subgroup (p = 0.003). Up-regulation of CEP72 was related to poor overall survival and event-free survival. PPI network showed that CEP72 was related to PCM1, KIZ, OFD1, etc. GSEA analysis showed that CEP72 was enriched in cell cycle, oocyte meiosis, protein export, lysosome and N-glycan biosynthesis pathways. Drug resistance analysis indicated that there was a positive correlation between the CEP72 expression and the IC50 values of 6-mercaptopurine, 8-chloro-adenosine, clofarabine, fludarabine and allopurinol.Conclusion: High CEP72 expression was a poor prognostic factor in patients diagnosed with multiple myeloma.


  • Open Access

    Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?

    by Yue Lv, Huiping Shi, Hong Liu, Lu Zhou

    Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder featured by increased platelet destruction and deficient megakaryocyte maturation. First-line treatments include corticosteroids, intravenous immunoglobulin and intravenous anti-D immunoglobulin. Second-line treatments consist of rituximab, thrombopoietin receptor agonists and splenectomy. Although most patients benefit from these treatments, an individualized treatment approach is warranted due to the large heterogeneity among ITP patients. In addition, ITP patients may relapse and there remains a subset of patients who become refractory to treatments. The management of these refractory patients is still a challenge. This review aims to summarize emerging therapeutic approaches for refractory ITP in several categories according to their different targets, including macrophages, platelets/megakaryocytes, T cells, B cells, and endothelial cells. Moreover, current management strategies and combination regimens of refractory ITP are also discussed.